Open an account

Zimmer Biomet Holdings

ZBH · NYSE

$96.00+$1.01 (+1.06%)TodayMarket closed ·
Prev close $94.99

About ZBH

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The company is headquartered in Warsaw Indiana, Indiana and currently employs 17,000 full-time employees. The company went IPO on 2001-07-25. The company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its segments include Americas, EMEA, and Asia Pacific. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. The company also focused on a suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Its portfolio features imageless robotics through its ROSA Robotics platform.

Employees
17,000
Headquarters
Warsaw Indiana, Indiana
Listed
Jul 25, 2001
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
zimmerbiomet.com

ZBH key statistics

Market cap
18.37B
Price-earnings ratio
23.06
Dividend yield
1.04%
Average volume
2.00M
Volume
1.21M
Open price
$96.13
High today
$96.90
Low today
$94.76
52 Week high
$106.88
52 Week low
$79.12

Zimmer Biomet Holdings (ZBH) at a glance

As of Oct 20, 2026, Zimmer Biomet Holdings (ZBH) shares are priced at $96.00, giving the company a market cap of 18.37B, a price-to-earnings ratio of 23.06 and a dividend yield of 1.04%.

Today the stock has traded between $94.76 and $96.90. The current price is 1.3% above the day's low and 0.9% below its high.

Volume so far is 1.21M shares, below the average of 2.00M shares a day.

Over the past year Zimmer Biomet Holdings has ranged from $79.12 to $106.88, and now sits 61% of the way up that range.

Zimmer Biomet Holdings met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported $2.07 per share against an estimate of $2.03.

The average analyst price target is $109.01, 13.6% above the current price, from 19 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

26%of 19 analyst ratings say Buy
  • Buy26.3%
  • Hold63.2%
  • Sell10.5%
Price target · 24 analystsAvg $109.01
Low
$93.93
Now
$96.00
High
$135.81

ZBH earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 3.0% on average.

  1. Q3 FY24: reported $1.74 per share against an estimate of $1.75
  2. Q4 FY24: reported $2.31 per share against an estimate of $2.32
  3. Q1 FY25: reported $1.81 per share against an estimate of $1.79
  4. Q2 FY25: reported $2.07 per share against an estimate of $2.00
  5. Q3 FY25: reported $1.90 per share against an estimate of $1.89
  6. Q4 FY25: reported $2.42 per share against an estimate of $2.42
  7. Q1 FY26: reported $2.09 per share against an estimate of $1.88
  8. Q2 FY26: reported $2.07 per share against an estimate of $2.03

ZBH news

  • Press releasePRNewswire

    ZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT

  • Rishabh Mishra

    Michael Burry Warns Anthropic’s Valuation Could Buy 78 Profitable S&P 500 Companies: ‘Fun Game in Times Like These’

  • Press releasePRNewswire

    Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results

  • Press releasePRNewswire

    Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation

  • Press releasePRNewswire

    Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026

  • Press releasePRNewswire

    Zimmer Biomet Announces Second Quarter 2026 Financial Results

  • Press releasePRNewswire

    Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

  • Press releasePRNewswire

    Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

Similar companies

Companies in the same industry as Zimmer Biomet Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.